MX2021004603A - Dosificacion. - Google Patents

Dosificacion.

Info

Publication number
MX2021004603A
MX2021004603A MX2021004603A MX2021004603A MX2021004603A MX 2021004603 A MX2021004603 A MX 2021004603A MX 2021004603 A MX2021004603 A MX 2021004603A MX 2021004603 A MX2021004603 A MX 2021004603A MX 2021004603 A MX2021004603 A MX 2021004603A
Authority
MX
Mexico
Prior art keywords
human
administering
dosing
antagonist
dose
Prior art date
Application number
MX2021004603A
Other languages
English (en)
Inventor
Patrick Mayes
Elaine Marie Paul
Catherine E Ellis
Jessica Katz
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2021004603A publication Critical patent/MX2021004603A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a un método de tratamiento de cáncer en un humano en necesidad del mismo, el método comprende administrar al humano una proteína agonista de unión a ICOS o porción de unión a antígeno de la misma a una dosis de cerca de 0.08 5 mg a cerca de 240 mg y administrar al humano un antagonista de PD1.
MX2021004603A 2018-10-22 2019-10-21 Dosificacion. MX2021004603A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862748595P 2018-10-22 2018-10-22
US201962807897P 2019-02-20 2019-02-20
US201962837385P 2019-04-23 2019-04-23
US201962895229P 2019-09-03 2019-09-03
US201962902444P 2019-09-19 2019-09-19
PCT/US2019/057251 WO2020086476A1 (en) 2018-10-22 2019-10-21 Dosing

Publications (1)

Publication Number Publication Date
MX2021004603A true MX2021004603A (es) 2021-09-08

Family

ID=68542765

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004603A MX2021004603A (es) 2018-10-22 2019-10-21 Dosificacion.

Country Status (9)

Country Link
US (1) US20210324081A1 (es)
EP (2) EP3870219A1 (es)
JP (2) JP2022505524A (es)
CN (2) CN113453715A (es)
AU (1) AU2019366321A1 (es)
BR (2) BR112021007517A2 (es)
CA (2) CA3116584A1 (es)
MX (1) MX2021004603A (es)
WO (2) WO2020086476A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230504A1 (en) * 2022-05-25 2023-11-30 Xencor, Inc. Methods for treating solid tumors using icos x pd-1 bispecific antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
JP5575636B2 (ja) 2007-05-07 2014-08-20 メディミューン，エルエルシー 抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
BRPI0917891A2 (pt) 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
CA2736816C (en) 2008-09-12 2018-05-22 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
JP2012501670A (ja) 2008-09-12 2012-01-26 アイシス・イノベーション・リミテッド Ｐｄ−１特異抗体およびその使用
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
EP2358392B1 (en) * 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
LT4209510T (lt) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
JP6220774B2 (ja) 2011-03-31 2017-10-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｉｃｏｓに対する抗体及びその使用
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014033327A1 (en) 2012-09-03 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos for treating graft-versus-host disease
CA3139031A1 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
KR20230164243A (ko) 2015-03-23 2023-12-01 조운스 테라퓨틱스, 인크. Icos에 대한 항체
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
BR102016021139B1 (pt) 2016-09-13 2021-11-30 Tupy S.A. Liga de ferro fundido vermicular e cabeçote de motor a combustão interna
US11884738B2 (en) * 2017-03-31 2024-01-30 The University Of North Carolina At Chapel Hill Methods and compositions for activation of T cells using nanoparticles conjugated with multiple ligands for binding receptors on T cells
WO2018187191A1 (en) * 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途

Also Published As

Publication number Publication date
EP3870219A1 (en) 2021-09-01
CA3116584A1 (en) 2020-04-30
WO2020086476A1 (en) 2020-04-30
EP3870220A1 (en) 2021-09-01
AU2019366321A1 (en) 2021-05-13
BR112021007082A2 (pt) 2021-08-03
JP2022505524A (ja) 2022-01-14
BR112021007517A2 (pt) 2021-10-26
WO2020086479A1 (en) 2020-04-30
CN113226369A (zh) 2021-08-06
CN113453715A (zh) 2021-09-28
US20210324081A1 (en) 2021-10-21
JP2022513374A (ja) 2022-02-07
WO2020086479A9 (en) 2020-06-18
CA3117746A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MX2020011546A (es) Anticuerpos anti-msr1 y metodos de uso de los mismos.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2020010144A (es) Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38).
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
CR20210272A (es) Anticuerpos humanizados contra c-kit
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
MX2020009468A (es) Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
MX2021001902A (es) Anticuerpos que se unen a histona 2a y/o 4 citrulinada.
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
NZ762312A (en) Anti-pacap antibody
MX2021004603A (es) Dosificacion.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2019011958A (es) Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye.
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
EP4076482A4 (en) COMPOSITIONS FOR MODULATING INTESTINAL MICROFLORA POPULATIONS, IMPROVING THE EFFECTIVENESS OF DRUGS AND TREATING CANCER, AND METHODS FOR THE PRODUCTION AND USE OF THE SAME
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы